Oragenics, Inc. to Host Management Update Webinar on May 20, 2025 to Discuss Concussion Treatment Landscape, ONP-002 Clinical Program, and Strategic Vision

Core Insights - Oragenics, Inc. is hosting a management update webinar on May 20, 2025, to discuss the unmet medical need in concussion treatment and its lead program ONP-002, a neuroprotective therapy for mild traumatic brain injury [1][3][6] - The company emphasizes that ONP-002 offers a novel therapeutic approach in a market lacking FDA-approved drug therapies for concussions [3] Company Overview - Oragenics is focused on developing intranasal therapeutics for neurological disorders, particularly ONP-002 for mild traumatic brain injury or concussion [4] - The company is advancing proprietary powder formulations and intranasal delivery technology to enhance drug administration [4] Product Development - ONP-002 is delivered intranasally, allowing for non-invasive and direct brain delivery while minimizing systemic exposure [3] - Preclinical studies have shown that ONP-002 can reduce inflammation, oxidative stress, and brain swelling following head injury, with a Phase I trial indicating the compound is safe and well tolerated [3]